Thrivent Financial for Lutherans Trims Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Thrivent Financial for Lutherans trimmed its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 87,612 shares of the biopharmaceutical company’s stock after selling 5,538 shares during the period. Thrivent Financial for Lutherans’ holdings in Catalyst Pharmaceuticals were worth $1,742,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in CPRX. GAMMA Investing LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 681 shares during the last quarter. nVerses Capital LLC bought a new position in Catalyst Pharmaceuticals in the third quarter worth approximately $50,000. CWM LLC boosted its stake in shares of Catalyst Pharmaceuticals by 686.5% during the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at $70,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $153,000. 79.22% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the transaction, the insider now directly owns 51,391 shares in the company, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Trading Down 1.2 %

Shares of CPRX opened at $22.07 on Friday. Catalyst Pharmaceuticals, Inc. has a 12-month low of $13.00 and a 12-month high of $24.27. The company has a market capitalization of $2.63 billion, a PE ratio of 18.70, a price-to-earnings-growth ratio of 3.44 and a beta of 0.75. The business’s 50 day moving average is $21.23 and its 200 day moving average is $18.72.

Analysts Set New Price Targets

CPRX has been the topic of several analyst reports. Truist Financial lifted their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Stephens assumed coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Citigroup upped their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $31.14.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.